MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565015 | Name: BM573

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BM573 is a dual thromboxane synthase inhibitor and thromboxane receptor antagonist.

Chemical Structure

BM573
BM573
CAS#284464-83-1

Theoretical Analysis

MedKoo Cat#: 565015

Name: BM573

CAS#: 284464-83-1

Chemical Formula: C18H22N4O5S

Exact Mass: 406.1311

Molecular Weight: 406.46

Elemental Analysis: C, 53.19; H, 5.46; N, 13.78; O, 19.68; S, 7.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BM573; BM-573; BM 573;
IUPAC/Chemical Name
N-[[(1,1-Dimethylethyl)amino]carbonyl]-2-[(4-methylphenyl)amino]-5-nitro-benzenesulfonamide
InChi Key
SILRUCMXYIKULW-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H22N4O5S/c1-12-5-7-13(8-6-12)19-15-10-9-14(22(24)25)11-16(15)28(26,27)21-17(23)20-18(2,3)4/h5-11,19H,1-4H3,(H2,20,21,23)
SMILES Code
O=S(C1=CC([N+]([O-])=O)=CC=C1NC2=CC=C(C)C=C2)(NC(NC(C)(C)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 406.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Romero M, Leon-Gomez E, Lobysheva I, Rath G, Dogné JM, Feron O, Dessy C. Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis. PLoS One. 2016 Mar 28;11(3):e0152579. doi: 10.1371/journal.pone.0152579. eCollection 2016. PubMed PMID: 27019366; PubMed Central PMCID: PMC4809599. 2: Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, Michiels C, Pirotte B, Masereel B, Sakalihassan N, Defraigne JO, Dogné JM. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins Other Lipid Mediat. 2011 Apr;94(3-4):124-32. doi: 10.1016/j.prostaglandins.2011.03.001. Epub 2011 Mar 21. PubMed PMID: 21397034. 3: Courtois A, Makrygiannis G, Cheramy-Bien JP, Purnelle A, Pirotte B, Dogne JM, Hanson J, Defraigne JO, Drion P, Sakalihasan N. Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms. Curr Drug Targets. 2018;19(11):1247-1255. doi: 10.2174/1389450119666171227224314. PubMed PMID: 29284385. 4: Bambi-Nyanguile SM, Hanson J, Ooms A, Alpan L, Kolh P, Dogné JM, Pirotte B. Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists. Eur J Med Chem. 2013 Jul;65:32-40. doi: 10.1016/j.ejmech.2013.04.033. Epub 2013 Apr 23. PubMed PMID: 23688698. 5: Tang L, Ding T, Praticò D. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice. Atherosclerosis. 2008 Aug;199(2):265-70. doi: 10.1016/j.atherosclerosis.2007.11.038. Epub 2008 Jan 22. PubMed PMID: 18206890. 6: Cyrus T, Yao Y, Ding T, Dogné JM, Praticò D. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol. 2007 Apr 30;561(1-3):105-11. Epub 2007 Jan 19. PubMed PMID: 17306791. 7: Kolh P, Rolin S, Tchana-Sato V, Pétein M, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Masereel B, D'Orio V, Dogne JM. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Prostaglandins Other Lipid Mediat. 2006 Mar;79(1-2):53-73. Epub 2005 Dec 22. PubMed PMID: 16516810. 8: Tchana-Sato V, Dogné JM, Lambermont B, Ghuysen A, Magis D, Morimont P, Hanson J, D'Orio V, Limet R, Kolh P. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Prostaglandins Other Lipid Mediat. 2005 Dec;78(1-4):82-95. Epub 2005 Jun 20. PubMed PMID: 16303607. 9: Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev. 2005 Spring;23(1):1-14. Review. PubMed PMID: 15867944. 10: Ghuysen A, Lambermont B, Dogné JM, Kolh P, Tchana-Sato V, Morimont P, Magis D, Hanson J, Segers P, D'Orio V. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol Exp Ther. 2004 Sep;310(3):964-72. Epub 2004 Apr 30. PubMed PMID: 15121765. 11: Lambermont B, Ghuysen A, Dogné JM, Kolh P, Tchana-Sato V, Morimont P, Benoit P, Gérard P, Masereel B, D'Orio V. Effects of BM-573, a novel thromboxane A2 inhibitor, on pulmonary hemodynamics in endotoxic shock. Arch Physiol Biochem. 2003 Jul;111(3):224-31. PubMed PMID: 14972744. 12: Lambermont B, Kolh P, Dogné JM, Ghuysen A, Tchana-Sato V, Morimont P, Benoit P, Gérard P, Masereel B, Limet R, D'Orio V. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitor. Arch Physiol Biochem. 2003 Jul;111(3):217-23. PubMed PMID: 14972743. 13: Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther. 2004 May;309(2):498-505. Epub 2004 Jan 23. PubMed PMID: 14742735. 14: Rolin S, Petein M, Tchana-Sato V, Dogne JM, Benoit P, Lambermont B, Ghuysen A, Kolh P, Masereel B. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther. 2003 Jul;306(1):59-65. Epub 2003 Apr 29. PubMed PMID: 12721335. 15: Rolin S, Dogné JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids. 2001 Aug;65(2):67-72. PubMed PMID: 11545621.